Fulcrum Therapeutics discontinued its lead SCD drug pociredir after the FDA raised cancer risk concerns linked to the drug's mechanism (PRC2 inhibition), similar to risks seen with Ipsen's withdrawn Tazverik.

Fulcrum Therapeutics (stock down 52%, exploring sale), SCD patients awaiting new oral options, and competitors in the SCD space (e.g., Vertex/CRISPR, bluebird bio, Pfizer) who may see shifts in pipeline positioning.

What should teams watch next?

Fulcrum's strategic review outcome (potential asset sale or M&A), FDA's evolving stance on PRC2 inhibitors in non-oncology indications, and any read-through to other SCD programs with epigenetic targets.

FDA Cancer Risk Concerns Sink Fulcrum SCD Drug: Pipeline Impact

FDA Concerns About Cancer Risk Sink Fulcrum Therapeutics’ Sickle Cell Disease Drug: Implications for SCD Pipeline and BD Strategy

0% citation coverage

Fulcrum Therapeutics is discontinuing its lead sickle cell disease drug, pociredir, after the FDA raised concerns about cancer risk. The decision, which sent shares down 52%, reshapes the SCD competitive landscape and opens strategic questions for pipeline watchers and BD teams.

Dr. Sarah Mitchell PharmD, RPh · Senior FDA Regulatory Correspondent

Reviewed by Dr. Sarah Chen Pharmaceutical Sciences Editor

Thursday, June 4, 2026 4 min read Updated Jun 4, 2026 Your watchlist

Executive Summary

Fulcrum Therapeutics halted pociredir development after the FDA flagged emerging data showing higher-than-expected rates of secondary blood cancers, a safety signal tied to the same class as Ipsen's withdrawn drug Tazverik.

The company's stock cratered 52% on the news, and Fulcrum is now exploring strategic alternatives including a potential sale of the company or its assets.

The loss of this oral PRC2 inhibitor removes a promising late-stage candidate from the sickle cell disease pipeline, potentially strengthening the competitive position of approved gene therapies like Casgevy and Lyfgenia as well as oral options such as Pfizer's voxelotor.

Regulatory	medium
Commercial	medium
Competitive	high
Investment	medium

Regulatory

medium

Commercial

medium

Competitive

high

Investment

medium

FDA Cancer Risk Fears Sink Fulcrum's SCD Drug

Key Takeaways

Fulcrum Therapeutics halted pociredir development after the FDA flagged emerging data showing higher-than-expected rates of secondary blood cancers, a safety signal tied to the same class as Ipsen's withdrawn drug Tazverik.
The company's stock cratered 52% on the news, and Fulcrum is now exploring strategic alternatives including a potential sale of the company or its assets.
The loss of this oral PRC2 inhibitor removes a promising late-stage candidate from the sickle cell disease pipeline, potentially strengthening the competitive position of approved gene therapies like Casgevy and Lyfgenia as well as oral options such as Pfizer's voxelotor.

The Development

On June 2, 2026, Fulcrum Therapeutics announced it would discontinue development of pociredir, its oral PRC2 inhibitor for sickle cell disease, following FDA concerns about cancer risk. According to reports, FDA staff flagged emerging data showing higher-than-expected rates of secondary blood cancers in patients treated with pociredir, a safety profile that mirrors the one seen with Ipsen's Tazverik (tazemetostat), which was withdrawn globally. Fulcrum's stock dropped 52% in response. The company stated it would explore strategic alternatives, including a potential sale of the company or its assets.

Pociredir had generated encouraging early clinical data in a disease with few treatment options, making it one to watch. The FDA's concern was explicitly tied to the secondary malignancies observed with Tazverik, another PRC2 inhibitor, raising a class-level safety question that now shadows other programs targeting epigenetic modifiers in non-oncology indications.

What This Means for the SCD Pipeline

For analysts and BD teams, this event has several layers. First, it removes a late-stage oral SCD contender from the pipeline, potentially strengthening the case for approved gene therapies such as Casgevy and Lyfgenia, as well as other oral options like Pfizer's voxelotor. The competitive dynamics in sickle cell disease now shift decisively toward these remaining therapies.

Second, the FDA safety signal around PRC2 inhibitors may create headwinds for other development programs that aim to use epigenetic modifiers outside of oncology. Companies with early-stage PRC2 assets in non-cancer indications should expect heightened regulatory scrutiny and may need to generate additional preclinical safety data before advancing into the clinic.

What Strategic Options Does Fulcrum Face?

Fulcrum's strategic review could present an acquisition opportunity for companies seeking to bolster their rare disease pipeline, though the pociredir asset itself carries significant regulatory risk. The company may also opt to sell non-pociredir assets or pursue a merger. BD teams should monitor Fulcrum's asset sale process closely, as the outcome will set a precedent for how the market values PRC2 inhibitors with known class-level safety concerns.

The broader lesson for pharma strategy is clear: regulatory risk tied to class-level toxicity can upend even well-regarded programs. Teams evaluating epigenetic drugs for non-oncology indications should factor in the potential for FDA to require long-term carcinogenicity data before approving pivotal trials.

Frequently Asked Questions

Why did the FDA raise concerns about pociredir?

The FDA flagged emerging data from pociredir trials showing higher-than-expected rates of secondary blood cancers, similar to the malignancies seen with Ipsen's Tazverik (tazemetostat), which was withdrawn globally. The concern is a class-level risk for PRC2 inhibitors.

How will this affect the sickle cell disease treatment landscape?

The removal of pociredir, a promising oral candidate, strengthens the competitive position of approved gene therapies (Casgevy, Lyfgenia) and other oral options like Pfizer's voxelotor. It also narrows the pipeline of late-stage oral treatments for SCD, a disease with limited therapeutic options.

What should BD teams watch for next?

BD teams should monitor Fulcrum's strategic review process, which may include a sale of the company or its assets. They should also track how the FDA applies this PRC2 safety precedent to other epigenetic modifier programs in non-oncology indications, as it could reshape development timelines and regulatory strategy across the class.